The Effects of HER2 on CDK4/6 Activity in Breast Cancer
Author:
Funder
Ohio State University
Center for Clinical and Translational Science, University of Utah
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference43 articles.
1. Cancer statistics, 2019;Siegel;CA Cancer J Clin,2019
2. CDK4/6 inhibition in breast cancer: current practice and future directions;Pernas;Ther Adv Med Oncol,2018
3. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes;Lundberg;Mol Cell Biol,1998
4. Control of the cell cycle and apoptosis;Lundberg;Eur J Cancer,1999
5. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status;Howlader;JNCI J Natl Cancer Inst,2014
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Clinical efficacy of CDK4/6 inhibitor plus endocrine therapy in HR-positive/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials;eBioMedicine;2024-07
2. Recent progress of CDK4/6 inhibitors’ current practice in breast cancer;Cancer Gene Therapy;2024-02-26
3. Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer;Frontiers in Oncology;2024-01-16
4. Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial;Nature Communications;2023-10-07
5. CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer;Cancers;2023-03-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3